Driving Collaborative Efforts for the Treatment of Hepatitis B with Johnson and Johnson Innovation.
Around the world, nearly 300 million people are chronically infected with hepatitis B today with less than five million of those diagnosed currently receive treatment.[1] Approximately three-quarters of people affected are living in the Asia Pacific–15 to 25 percent of them will eventually die of HBV‐related liver disease.[2] While treatments for chronic hepatitis B exist, those living with the disease are burdened by stigma, disease progression and lifelong daily treatment.[3]
Through collaboration, Janssen Infectious Diseases & Vaccines is determined to look for a functional cure for chronic hepatitis B, with the aim to help reduce the burden and improve health outcomes for the millions of people living with the disease. In this webinar, Johnson & Johnson Innovation and global R&D leaders from the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) will convene with key opinion leaders to discuss the major opportunities and challenges in accelerating transformational potential solutions and medicines for patients living with the virus in Asia Pacific and worldwide.
In this effort, Janssen is keen to explore working with regional scientists and innovators. We will be hosting 1:1 partnering meetings with selected companies to discuss their respective potential solutions. Scroll down for further details on how to apply.
RELEVANT SUSTAINABLE GOALS
Driving Collaborative Efforts for the Treatment of Hepatitis B
Johnson & Johnson Innovation is looking for
- Transformational science that enables us to expedite vaccine development and pursue next-generation therapeutics.
- Novel compounds and platforms of high therapeutic potential
We Johnson & Johnson is agnostic to platforms and modalities, which can include small molecules, biologics, and RNA therapeutics.
Johnson & Johnson Innovation is interested in developing therapeutics and vaccines for infectious diseases, including
- Viral hepatitis & adjacent liver diseases
- Prevention & treatment of viral & bacterial respiratory infections & Acute Respiratory Distress Syndrome (ARDS)
- Novel vaccines, viral vectors & adjuvants & vaccine technologies
Before you request a 1:1 meeting with our team, we encourage you to join our “Driving Collaborative Efforts for the Treatment of Hepatitis B” webinar (register below).
APPLICATION PROCESS
1. Register for the webinar at the top right of this screen
2. Apply for the 1:1 meetings at the button below
3. Create an account on Survey Monkey Apply if you don’t already have one
4. Fill in the application form and upload a slide deck or one-pager (all information should be non-confidential)
5. Submit by Friday, 10 June
6. Selected companies will receive an email invitation to confirm a mutually agreed time
7. Once notified, confirm attendance of your 1:1 meeting within 48 hours
Those interested in being considered for a 1:1 virtual meeting opportunity must apply by Friday, 10 June, by submitting a request form that includes non-confidential information. The selected participants will be invited for a 1:1 virtual meeting with an appropriate representative immediately following the webinar or at a mutually convenient time.
If you come across any issues with the application form, please contact JJIAP@its.jnj.com
You may also be interested in :
Plant Power : Embracing Plant-Based And Flexitarian Diet For The Future
Never miss a story. Join us on social.